Substance / Medication

Diazoxide

Overview

Active Ingredient
diazoxide
RxNorm CUI
3327

Indications

Diazoxide oral suspension is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Diazoxide oral suspension should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide oral suspension should be considered. Adults: Inoperable islet cell adenoma or

Labeler: Par Health USA, LLCUpdated: 2025-12-29T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Diazoxide oral suspension is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in diazoxide oral suspension, or other thiazides

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis.
Chen Xiaohong, Feng Lifang, Yao Hui et al. · PLoS One · 2021
PMID: 33571197Meta-AnalysisFull text (PMC)
Diazoxide for Severe or Recurrent Neonatal Hypoglycemia: A Randomized Clinical Trial.
Laing Don, Walsh Eamon P G, Alsweiler Jane M et al. · JAMA Netw Open · 2024
PMID: 38869900RCTFull text (PMC)
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Miller Jennifer L, Gevers Evelien, Bridges Nicola et al. · J Clin Endocrinol Metab · 2023
PMID: 36639249RCTFull text (PMC)
Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability.
Kadriu Bashkim, Yuan Shiwen, Farmer Cristan et al. · J Clin Psychopharmacol · 2018
PMID: 29601316RCTFull text (PMC)
High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention.
Loves Sandra, van Groningen Lenneke, Filius Margreet et al. · J Clin Endocrinol Metab · 2018
PMID: 30202851RCT
Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men.
Loves Sandra, van Groningen Lenneke, Filius Margreet et al. · J Clin Endocrinol Metab · 2018
PMID: 29618011RCT
Diazoxide in Children With Obesity After Hypothalamic-Pituitary Lesions: A Randomized, Placebo-Controlled Trial.
Brauner Raja, Serreau Raphaël, Souberbielle Jean-Claude et al. · J Clin Endocrinol Metab · 2016
PMID: 27603903RCT
Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes.
George Priya S, Tavendale Roger, Palmer Colin N A et al. · Diabetes · 2015
PMID: 25591873RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Diazoxide (substance)
SNOMED CT
387328001
UMLS CUI
C0012022
RxNorm CUI
3327
Labeler
Par Health USA, LLC

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.